Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 109, Issue 12, Pages 3993-4002
Publisher
Wiley
Online
2018-11-17
DOI
10.1111/cas.13806
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
- (2018) Masahiro Matsuki et al. Cancer Medicine
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- International incidence and mortality trends of liver cancer: a global profile
- (2017) Martin C. S. Wong et al. Scientific Reports
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
- (2016) Tai Hato et al. Immunotherapy
- Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation
- (2016) Thomas Welte et al. NATURE CELL BIOLOGY
- Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
- (2016) R. F. Sweis et al. Cancer Immunology Research
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
- (2015) M. Ikeda et al. CLINICAL CANCER RESEARCH
- Global Epidemiology of Hepatocellular Carcinoma
- (2015) Katherine A. McGlynn et al. Clinics in Liver Disease
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
- (2015) Hui Gao et al. NATURE MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
- (2013) El-ad David Amir et al. NATURE BIOTECHNOLOGY
- Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
- (2011) Seth B. Coffelt et al. JOURNAL OF IMMUNOLOGY
- SEURAT: Visual analytics for the integrated analysis of microarray data
- (2010) Alexander Gribov et al. BMC Medical Genomics
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients
- (2009) Valerie Chew et al. JOURNAL OF HEPATOLOGY
- Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade
- (2009) Nobuhiro Nakamoto et al. PLoS Pathogens
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More